Anti-HER2/neu therapy in DCIS

Amelia Tower; Ruta D. Rao; Kalliopi P. Siziopikou; Melody A. Cobleigh; Thomas B. Julian

doi:10.1007/978-1-4939-2035-8_10

Anti-HER2/neu therapy in DCIS

Amelia Tower, Ruta D. Rao, Kalliopi P. Siziopikou, Melody A. Cobleigh, Thomas B. Julian^*

^*Corresponding author for this work

Pathology

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Ductal carcinoma in situ (DCIS) is a heterogeneous form of preinvasive breast cancer, with subtypes that are comparable to those of invasive disease. Targeted molecular therapies have improved outcomes for patients with invasive breast cancer, and we have parallel opportunities for advances in personalized treatment of DCIS. Early work has demonstrated synergy between human epidermal growth factor receptor (HER)2-targeted therapy and radiotherapy. Anti-HER2 therapy may also induce an immune response. This chapter addresses the history of research regarding HER2 expression in DCIS as well as ongoing clinical trials that address whether HER2-targeted therapy will improve patient outcomes in DCIS.

Original language	English (US)
Title of host publication	Ductal Carcinoma in Situ and Microinvasive/Borderline Breast Cancer
Publisher	Springer New York
Pages	99-108
Number of pages	10
ISBN (Electronic)	9781493920358
ISBN (Print)	9781493920341
DOIs	https://doi.org/10.1007/978-1-4939-2035-8_10
State	Published - Jan 1 2015

Keywords

Ductal carcinoma in situ
HER2/neu
Radiotherapy
Trastuzumab

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/978-1-4939-2035-8_10

Cite this

@inbook{5f7c68016b034e74bfbb987f1a57bea6,

title = "Anti-HER2/neu therapy in DCIS",

abstract = "Ductal carcinoma in situ (DCIS) is a heterogeneous form of preinvasive breast cancer, with subtypes that are comparable to those of invasive disease. Targeted molecular therapies have improved outcomes for patients with invasive breast cancer, and we have parallel opportunities for advances in personalized treatment of DCIS. Early work has demonstrated synergy between human epidermal growth factor receptor (HER)2-targeted therapy and radiotherapy. Anti-HER2 therapy may also induce an immune response. This chapter addresses the history of research regarding HER2 expression in DCIS as well as ongoing clinical trials that address whether HER2-targeted therapy will improve patient outcomes in DCIS.",

keywords = "Ductal carcinoma in situ, HER2/neu, Radiotherapy, Trastuzumab",

author = "Amelia Tower and Rao, {Ruta D.} and Siziopikou, {Kalliopi P.} and Cobleigh, {Melody A.} and Julian, {Thomas B.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1007/978-1-4939-2035-8_10",

language = "English (US)",

isbn = "9781493920341",

pages = "99--108",

booktitle = "Ductal Carcinoma in Situ and Microinvasive/Borderline Breast Cancer",

publisher = "Springer New York",

}

TY - CHAP

T1 - Anti-HER2/neu therapy in DCIS

AU - Tower, Amelia

AU - Rao, Ruta D.

AU - Siziopikou, Kalliopi P.

AU - Cobleigh, Melody A.

AU - Julian, Thomas B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Ductal carcinoma in situ (DCIS) is a heterogeneous form of preinvasive breast cancer, with subtypes that are comparable to those of invasive disease. Targeted molecular therapies have improved outcomes for patients with invasive breast cancer, and we have parallel opportunities for advances in personalized treatment of DCIS. Early work has demonstrated synergy between human epidermal growth factor receptor (HER)2-targeted therapy and radiotherapy. Anti-HER2 therapy may also induce an immune response. This chapter addresses the history of research regarding HER2 expression in DCIS as well as ongoing clinical trials that address whether HER2-targeted therapy will improve patient outcomes in DCIS.

AB - Ductal carcinoma in situ (DCIS) is a heterogeneous form of preinvasive breast cancer, with subtypes that are comparable to those of invasive disease. Targeted molecular therapies have improved outcomes for patients with invasive breast cancer, and we have parallel opportunities for advances in personalized treatment of DCIS. Early work has demonstrated synergy between human epidermal growth factor receptor (HER)2-targeted therapy and radiotherapy. Anti-HER2 therapy may also induce an immune response. This chapter addresses the history of research regarding HER2 expression in DCIS as well as ongoing clinical trials that address whether HER2-targeted therapy will improve patient outcomes in DCIS.

KW - Ductal carcinoma in situ

KW - HER2/neu

KW - Radiotherapy

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84944518884&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944518884&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-2035-8_10

DO - 10.1007/978-1-4939-2035-8_10

M3 - Chapter

AN - SCOPUS:84944518884

SN - 9781493920341

SP - 99

EP - 108

BT - Ductal Carcinoma in Situ and Microinvasive/Borderline Breast Cancer

PB - Springer New York

ER -

Anti-HER2/neu therapy in DCIS

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this